Piramal Pharma Limited

Overview

Piramal Pharma Limited is a leading Indian pharmaceutical company that focuses on a diverse range of therapeutics, including proprietary products and contract manufacturing services. As a public entity, it operates with an emphasis on innovation and growth in the pharmaceutical industry.

Therapeutic areas

API / Drug Master Files

Piramal Pharma Limited holds 57 active (57 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• LIRAGLUTIDEActive2026-03-28
• SEMAGLUTIDEActive2026-03-13
• LANREOTIDEActive2025-07-30
• EDOXABAN TOSYLATE MONOHYDRATEActive2025-03-30
• LEVOKETOCONAZOLEActive2023-10-18
• ANAGRELIDE HYDROCHLORIDE MONOHYDRATEActive2023-05-26
• OXYTOCIN USPActive2023-03-06
• OCTREOTIDE ACETATEActive2021-11-16
• AZILSARTAN KAMEDOXOMILActive2021-03-31
• VORTIOXETINE HYDROBROMIDEActive2021-03-31
• BEXAGLIFLOZINActive2020-03-30
• CETRORELIXActive2020-03-19
• VARENICLINE TARTRATEActive2020-01-30
• DROXIDOPAActive2019-12-20
• DEXLANSOPRAZOLEActive2019-03-29

Showing 15 of 57 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Piramal Pharma Limited in our records. PharmaTek screens the full directory against live FDA enforcement data.